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Abstract  
Wnt/β-catenin signaling is a highly conserved pathway essential for 
embryogenesis and tissue homeostasis. However, deregulation of this 
pathway can initiate and promote human malignancies, especially of the colon 
and head and neck. Therefore, Wnt/β-catenin signaling represents an 
attractive target for cancer therapy. We performed high-throughput screening 
(HTS) using AlphaScreen and ELISA techniques to identify small molecules 
that disrupt the critical interaction between β-catenin and the transcription 
factor TCF4 required for signal transduction. We found that compound LF3, a 
4-thioureido-benzenesulfonamide derivative, robustly inhibited this interaction. 
Biochemical assays revealed clues that the core structure of LF3 was 
essential for inhibition. LF3 inhibited Wnt/β-catenin signals in cells with 
exogenous reporters and in colon cancer cells with endogenously high Wnt 
activity. LF3 also suppressed features of cancer cells related to Wnt signaling, 
including high cell motility, cell cycle progression, and the overexpression of 
Wnt target genes. However, LF3 did not cause cell death or interfere with 
cadherin-mediated cell-cell adhesion. Remarkably, the self-renewal capacity 
of cancer stem cells was blocked by LF3 in concentration-dependent manners, 
as examined by sphere formation of colon and head and neck cancer stem 
cells under non-adherent conditions. Finally, LF3 reduced tumor growth and 
induced differentiation in a mouse xenograft model of colon cancer. 
Collectively, our results strongly suggest that LF3 is a specific inhibitor of 
canonical Wnt signaling with anticancer activity that warrants further 
development for preclinical and clinical studies as a novel cancer therapy. 
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Introduction 
Great efforts have been made over the past two decades to develop rational 
targeted cancer therapies, which are more effective than chemo- and 
radiotherapies and may cause fewer side effects. Successes involve drugs 
that act as tyrosine kinase inhibitors; to date, 28 such substances have been 
approved for clinical use (1). Drugs that interfere with other fundamental 
signaling systems, such as γ-secretase inhibitors that target Notch signals (2) 
or inhibitors that target Sonic hedgehog (3), have been developed and are 
being evaluated in preclinical and clinical trials. Other signaling systems 
whose deregulation is essential in the initiation and maintenance of cancers – 
such as Wnt/β-catenin signaling – need to be identified and targeted as 
means of expanding the current repertoire of anti-tumor strategies (4).  
 
Wnt/β-catenin signaling is a system that is essential for embryonic 
development and tissue homeostasis that has been highly conserved 
throughout evolution (5-7). The key mediator of the pathway is β-catenin, a 
transcriptional co-activator whose level is tightly controlled by a multiprotein 
destruction complex in the cytoplasm. This complex is composed of Axin, 
adenomatous polyposis coli (APC), casein kinase 1α (CK1α), glycogen 
synthase kinase 3β (GSK3β) and β-transducin repeats containing protein (β-
TrCP). The latter phosphorylate β-catenin and induce its ubiquitination and 
proteosomal degradation. Canonical Wnt ligands such as Wnt1 or Wnt3a 
stimulate the pathway by inhibiting the destruction complex; this results in the 
stabilization and nuclear translocation of β-catenin. There β-catenin interacts 
with members of the TCF/LEF family of transcription factors and recruits a 
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number of coactivators including B-cell lymphoma 9 (BCL9) and CREB-
binding protein (CBP), ensuring efficient activation of Wnt target genes. A 
comprehensive list of Wnt target genes can be found at 
web.stanford.edu/group/nusselab/cgi-bin/wnt/.  
 
The discovery of an association between β-catenin and the tumor suppressor 
gene APC led to the recognition of the essential role of Wnt/β-catenin 
signaling in various cancers (8-11). Aberrant Wnt signaling is frequently 
caused by mutations in APC, β-catenin and Axin2. A noted exception is 
melanoma, where activated Wnt/β-catenin signaling appears to be associated 
with reduced tumor formation (12). Deregulated Wnt signaling is not only 
important for cancer initiation, but is also crucial in late-stage cancers and in 
metastasis formation (13, 14). Recent studies have shown that cancer stem 
cells (CSCs) in various tumors exhibit deregulated Wnt/β-catenin signaling 
(15-17) and require higher Wnt activity than differentiated cancer cells to 
maintain their self-renewal and tumorigenic properties. This feature may be 
useful in specifically targeting cancer stem cells, a crucial factor in combatting 
cancer recurrence (18, 19).  
 
Over the past decade, researchers in academia and industry have developed 
various strategies to identify small molecules that target components involved 
in Wnt signaling. Wnt inhibitors were initially identified through ELISA-based 
high Throughput Screening (HTS) of natural compounds that interfere with β-
catenin/TCF4 interactions (20). Cell-based HTS has been applied to identify 
additional small-molecule inhibitors of the pathway, some of which target Wnt 
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secretion (the porcupine inhibitor IWP-2) (21) or the Wnt receptor complex 
(Dishevelled/Frizzled interaction inhibitors NSC668036 and FJ9) (22, 23). 
Other compounds have been found that enhance the stability of the β-catenin 
destruction complex (tankyrase inhibitors XAV939 and JW55) (24, 25) or 
disrupt the transcription complex (β-catenin/CBP interaction inhibitor ICG-001, 
β-catenin/TCF interaction inhibitors iCRT3 and CWP232228, and β-
catenin/BCL9 interaction inhibitor carnosic acid) (26-29). These studies 
allowed the further development of small-molecule Wnt inhibitors that entered 
early clinical trials, including PRI-724, CWP232291 and LGK974 (30).  
 
In human cancer, activating mutations of Wnt signaling components are 
frequently found at the level of the destruction or transcription complexes. We 
reasoned that efforts to develop new Wnt inhibitors could therefore be 
directed to the downstream components of the pathway, in particular to the β-
catenin-TCF transcription complexes. This may require interference with 
protein-protein interactions, which is a challenging field of research (31). A 
further concern was the overlap of the binding sites of β-catenin with TCFs 
and E-cadherin, as seen in the structural analyses (32). Substances 
interfering with E-cadherin interaction could thus have opposing effects than 
interfering with Wnt signaling. We should however note that because of the 
much larger β-catenin/E-cadherin interaction surface, the Kd of this interaction 
can be 1000-fold lower than with the TCFs (33). β-Catenin/TCF4 interaction 
inhibitors have been recently described (27, 29), suggesting the great 
potential of such inhibitors to be developed for clinical use. 
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Here we took advantage of the AlphaScreen technology to perform HTS to 
identify small molecules that interfere with the interaction of β-catenin and 
TCF4. The compound LF3 was identified as a potent and specific inhibitor of 
activated Wnt/β-catenin signals in reporter cells, but it did not interfere with 
the interaction of β-catenin with E-cadherin. LF3 blocked properties related to 
Wnt addiction in colon cancer cells, including enhanced cell migration and the 
progression of the cell cycle, and interfered with the self-renewal of cancer 
stem cells. In a xenograft tumor model derived from colon cancer stem cells, 
LF3 did not only reduce tumor growth but also strongly induced tumor 
differentiation. We thus report on the discovery of a small-molecule Wnt 
inhibitor with promising chemical and biological properties, with a potential for 
further development into a lead compound for targeted therapies of Wnt-
addicted tumors. 
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Materials and Methods 
Cell culture 
The cell lines HCT116, HCT15, HT29, SW480, SW620, LS174T, SW48, 
MCF7, Hela, HEK293 and MDCK were obtained from the ATCC and cultured 
in DMEM (Invitrogen) supplemented with 10% fetal bovine serum, penicillin 
and streptomycin. Mouse salivary gland cancer stem cells were isolated and 
cultured in DMEM/F12 (Invitrogen) supplemented with 20% KSR, 
nonessential minimal amino acids, penicillin, streptomycin, L-glutamine and β-
mercaptoethanol. The cell identity was tested by PCR phenotyping for β-
catenin and Bmpr1a (16). 
Protein purification 
The cDNA encoding residues 134-668 of human β-catenin were inserted into 
the pGEX-4-T1 vector (GE Healthcare), and the cDNA encoding residues 1-
79 of human TCF4 were inserted into the pET-16b vector (Qiagen). A 
mutation of residue Asp16 of TCF4 was introduced by PCR mutagenesis with 
the primers: forward 5’-GACCTAGGCGCCAACGCCGAACTGATTTCCTTCA-
3’, and reverse 5’-TGAAGGAAATCAGTTCGGCGTTGGCGCCTAGGTC-3’. 
Recombinant fusion proteins were expressed in E. coli BL21 cells and purified 
through GSTrap FF or HisTrap FF columns (GE, details in Supplementary 
Materials and Methods). Biotinylated human TCF4 peptide (aa 8-53) was 
purchased from Biosyntan, Berlin, Germany. 
Compound library, compound analogs, High Throughput AlphaScreen 
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A library containing 16671 World Drug Index-derived compounds was 
provided by ChemBioNet, designed by the drug design and modeling group of 
the Leibniz-Institut für Molekulare Pharmakologie, Berlin, Germany (34). 
Analogs of LF3 were purchased from ChemDiv (San Diego, CA) and 
ChemBridge (San Diego, CA) and dissolved in DMSO to a concentration of 50 
mM. In the AlphaScreens, purified GST-hβ-catenin was first incubated with 
nickel chelate acceptor beads and His-hTCF4 incubated with glutathione 
donor beads (Perkinelmer) in PBS. They were then combined into 384-well 
AlphaPlates in the presence of 20 µM test compounds. Titration was used to 
determine the concentration of purified proteins used in the AlphaScreens, 
yielding signals in linear ranges. After 1 h incubation, protein-protein 
interactions induced luminescence, as measured by an EnVision multilabel 
plate reader (PerkinElmer, Waltham MA). 
Sphere culturing of cancer stem cells 
24-well cell culture plates were pre-coated with 250 μl polyhema (12 mg/ml in 
95% ethanol, Sigma) to promote the growth of non-attached spheres. SW480 
reporter cells and mouse salivary gland cancer stem cells were trypsinized 
and seeded as single cells into the sphere culture medium (F12:DMEM 1:1, 
1X B-27 supplement, 20 ng/ml EGF, 20 ng/ml FGF, 0.5% methylcellulose) 
with or without treatment (16, 19). After 10 days, spheres were counted under 
a phase contrast microscope, and pictures were taken by AF6000 and 
DFC350FX (Leica). 
Mouse xenografts and therapy with LF3 
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Unsorted GFPlow and GFPhigh SW480 cells (1×104) were subcutaneously 
injected into the back skin of NOD/SCID mice. Tumor growth was monitored 
over a period of 45 days. For therapy, LF3 was administered i.v. at 50 mg/kg 
body weight for 3 rounds over 5 consecutive days, with 2-day breaks. 
Gene expression profiling  
After desired treatments, total RNA of salivary gland CSCs were extracted 
according to the standard TRIzol protocol (Invitrogen). RNA was purified with 
RNeasy kit (Qiagen) and prepared with TotalPrep RNA amplification kit 
(Illumina) for the microarray analysis using MouseRef-8 v2.0 expression 
beadchip Kit. Microarray data (GEO accession: GSE73732) were analyzed 
and exported with the software Genome Studio (Illumina). Pearson correlation 
was calculated with http://www.wessa.net/rwasp_correlation.wasp. 
Expression clustering was calculated and visualized with software Cluster and 
TreeView (Stanford University), respectively. Functional clustering of 
interesting genes was performed with http://david.abcc.ncifcrf.gov/. 
The techniques ELISA, co-immunoprecipitation, Western blotting, the 
establishment of TOP-GFP reporter cell lines, Luciferase reporter assays, 
immunofluorescence, chromatin immunoprecipitation and gene transcription 
analyses with qRT-PCR, cell migration, proliferation with BrdU, cell death by 
apoptosis, cell cycle and cell surface marker analyses are described in 
Supplementary Materials and Methods. 
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Results 
High Throughput Screening and biochemical characterization of small 
molecules that interfere with the interaction of β-catenin and TCF4 
We performed AlphaScreen-based High Throughput Screenings (Fig. S1A 
(35)) with a library of 16,000 synthetic compounds (see Figure S1C) from the 
central open access technology platform of ChemBioNet (34), using a GST-
tagged armadillo repeat domain of human β-catenin (GST-β-catenin, aa 
residues 134-668) and a His-tagged N-terminal region of human TCF4 (His-
hTCF4, aa 1-79) (Fig. 1A (32, 36, 37), see Materials and Methods). The 
interaction between recombinant β-catenin and TCF4 was specific: in ELISA 
(Fig. S1B), binding could be inhibited by recombinant TCF4 (His-hTCF4) and 
an N-terminal peptide of TCF4 (Bio-TCFpeptide, aa 8-53), but not by TCF4 
mutated at critical Asp16 (His-TCF4(D16A)) (32, 36, 37) or irrelevant proteins 
(Fig. S1C). From the primary AlphaScreens, compounds that inhibited 
interactions by at least 40% at 20 µM were selected, and false positives 
(which also appeared in non-related screens) were excluded (see the course 
of the screening procedure in Fig. S1D). 132 compounds were re-examined 
using both AlphaScreens and ELISAs, and finally 5 compounds were 
identified (termed LF1 to LF5) that inhibited interactions by 50% at 
concentrations below 10 µM in both assays (Fig. S1E,F). Due to its excellent 
chemical properties and expected plasma membrane permeability (predicted 
by Lipinski’s rule (38)), compound LF3 (Fig. 1B, structure on the left) with an 
IC50 of less than 2 µM in both assays (Fig. 1B, right) was chosen for further 
studies. 
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To clarify the specific structural requirements of LF3, analogs were purchased 
and tested by ELISA. Deletion or replacement of the sulfonamide group (R1) 
by methyl, fluorine or nitro eliminated inhibitory activity (Fig. 1C). Deletion of 
the benzene tail (R2) strongly reduced activity (Fig. 1D). The distance 
between the benzene ring and core structure was also important; among the 
analogs with 2 or fewer methyl groups between the benzene and the core, 
only LF3h exhibited inhibitory activity as potent as that of LF3 in these 
biochemical experiments (Fig. 1D). 
Compound LF3 interferes with the interaction of endogenous proteins in 
cells and inhibits Wnt/β-catenin signaling in cellular assays 
To investigate the effects of LF3 on the interactions of endogenous cellular 
proteins, protein extracts from HCT116 cells were incubated with LF3 at 3.3 - 
60 µM, and β-catenin together with its binding partners were pulled down by 
co-immunoprecipitation using specific anti-β-catenin antibodies. LF3 interfered 
with both β-catenin/TCF4 and β-catenin/LEF1 interactions in dose-dependent 
manners, as shown by Western blotting (Fig. 2A, quantification in B). 
To evaluate biological activity, LF3 and analogs were examined for inhibition 
of Wnt/β-catenin signaling in stable HEK293 reporter cells that express GFP 
in a TCF/LEF-dependent fashion (TOP-GFP, SABiosciences). LF3 was the 
most potent inhibitor of TOP-GFP production with an IC50 of 22.2 ± 4.9 µM, 
when cells were stimulated with 3 µM of CHIR99021 (39), which is a GSK3β 
inhibitor and thus a Wnt activator (Fig. 2C,D). LF3h was less potent and was 
therefore not studied further. When compared with ICG-001 and XAV939, 
which are Wnt inhibitors that suppress Wnt signaling at the levels of nuclear 
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transcription and β-catenin destruction, respectively (scheme in Fig. S2A (25, 
30)), LF3 inhibited TOP-GFP signals with kinetics and at levels comparable to 
ICG-001, but different from XAV939 (Fig. S2B). Conventional TOPflash 
assays in HeLa cells showed that LF3 inhibited luciferase signals with IC50 
between  2.4 - 4.0 µM, which were stimulated by recombinant Wnt3a, 
CHIR99021 or overexpression of an activating β-catenin mutant (with four 
mutated N-terminal phosphorylation sites), but not by overexpression of a β-
catenin/LEF1-HMG fusion protein (40), which has no interface for LF3 binding 
(Fig. 2E). LF3 did not significantly inhibit other reporters, i.e., Oct-Luciferase 
stimulated by Oct4, NF-κB-Luciferase by TNFα, or Notch-Luciferase by NICD 
(SABiosciences, Fig. 2F, Fig. S2C). These data indicate that the inhibition of 
canonical Wnt signaling by LF3 in cells is specific and may indeed occur 
downstream in the pathway, i.e., at the β-catenin/TCF4 level. 
LF3 does not disturb E-cadherin-mediated cell adhesion 
Both TCF4 and E-cadherin interact with β-catenin through common armadillo 
repeats (32, 41, 42); this was a major concern as we developed our inhibitor, 
since a loss of function of β-catenin in adherens junctions might increase cell 
migration and induce metastasis (43). We therefore examined whether LF3 
might also disrupt the interaction between β-catenin and E-cadherin. 
Immunofluorescence staining of MDCK cells revealed that E-cadherin and β-
catenin co-localized at cell-cell adhesion sites and showed merged 
cobblestone patterns (Fig. S2D; upper panel, Fig. S2H; left panel). This 
location was not altered by LF3 treatment, for instance at 60 µM, which 
however strongly disturbed Wnt/β-catenin signaling at this concentration (Fig. 
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S2D, middle panel; see also above). In contrast, treatment of cells with 
hepatocyte growth factor (HGF) at 40U/ml leads to scattering of cells, to the 
loss of cell-cell adhesions and to a relocation of E-cadherin and β-catenin to 
non-overlapping cytoplasmic sites (Fig. S2D, lower panel). When β-catenin 
was immunoprecipitated from protein extracts of HCT116 cells incubated with 
increasing concentrations of LF3 at 3.3 - 60 µM, the amount of E-cadherin 
bound to β-catenin remained unchanged (Fig. S2E, quantification in F). 
MDCK cells were also incubated with LF3 and subjected to trypsin treatment 
for 5 min, which largely digested E-cadherin and abrogated E-cadherin-
mediated cell-cell adhesion (Fig. S2G, Fig. S2H; 2nd panel). After removing 
the trypsin, cells were allowed to reform E-cadherin/β-catenin complexes at 
cell-cell adhesions: in the presence of LF3, the time-course of recovery of E-
cadherin/β-catenin-mediated cell-cell adhesion was as in controls (Fig. S2H, 
3rd - 5th panel). Overall, these data show that LF3 inhibits Wnt/β-catenin 
signaling, but does not interfere with E-cadherin/β-catenin-mediated cell-cell 
adhesion. 
LF3 inhibits Wnt/β-catenin target gene expression and impairs Wnt-
associated properties of colon cancer cells  
In colon cancer cells that harbor Wnt/β-catenin-activating mutations, the Wnt 
target genes Axin2 and c-Myc are actively transcribed upon binding of β-
catenin/TCF4 to their promoter regions. Sequences near the promoters of 
Axin2 and c-Myc were enriched by anti-β-catenin chromatin 
immunoprecipitation (ChIP) from HCT116 cells, and the enrichments were 
significantly reduced by LF3 at 30 µM (Fig. 3A). As shown by qRT-PCR, LF3 
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at 10 - 60 µM also inhibited the expression of many Wnt target genes (Bmp4, 
Axin2, Survivin, c-Myc, Bambi and c-Myc) in a dosage-dependent manner 
(Fig. 3B); ICG-001 at 25 µM or siRNA treatment against β-catenin had similar 
effects. The production of Axin2, c-Myc and cyclinD1 proteins was also 
suppressed by LF3 at 30 µM in a panel of colon cancer cell lines (Fig. 3C-F, 
Fig. S3A-H). Thus, LF3 blocks the expression of a series of Wnt target genes 
in Wnt-addicted colon cancer cells. 
Wnt/β-catenin signaling contributes to high cell motility, high cell proliferation 
and cell cycle progression in colon cancer cells. Boyden chamber motility 
assays with SW480 colon cancer cells showed that LF3 at 10 and 30 µM 
strongly reduced cell migration in a dosage-dependent manner (Fig. 4A). LF3 
at 30 and 60 µM also reduced proliferation, as measured by BrdU-
incorporation, in the Wnt-dependent colon cancer cell lines HCT116 and 
HT29, but not in the Wnt-independent breast cancer cell line MCF7 (Fig. 4B). 
Cleaved caspase3 and propidium iodide staining indicated that the inhibition 
of proliferation, for instance in HCT116 cells, was not due to apoptotic or 
cytotoxic effects of LF3 at 60 µM, which are induced in cells by puromycin at 1 
µg/ml (Fig. S4A,B). Instead, we observed that LF3 at 30 and 60 µM induced 
cell cycle arrest in the G1 phase of HCT116 and HT29 cells in dosage-
dependent manners (Fig. 4C), but had only an insignificant influence on the 
cell cycle of MCF7 cells. These data show that LF3 inhibits proliferation of 
Wnt-addicted colon cancer cells through induction of cell cycle arrest.   
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LF3 inhibits the self-renewal capacity of cancer stem cells 
It has been reported that high Wnt/β-catenin activity characterizes colon 
cancer stem cells and other cancer stem cells, which are fractions of tumor 
cells capable of regenerating entire tumors following transplantation (18, 19, 
44). A small molecule Wnt inhibitor CWP232228 has recently been shown to 
be able to inhibit the proliferation of breast cancer stem cells (29). Stem and 
cancer stem cells are generally enriched in non-attached sphere cultures, 
which reflect their self-renewal capacity (45, 46). We asked whether LF3 
could specifically target colon and salivary gland cancer stem cells through 
Wnt/β-catenin inhibition. A reporter cell line that expressed TOP-GFP (see 
above) was generated from SW480 colon cancer cells. Flow cytometry 
analysis revealed heterogeneous expression of GFP in this cell line (Fig. 5A). 
GFP intensity correlated with Wnt/β-catenin activity, as shown by upregulated 
mRNA and protein levels of Wnt target genes (Bmp4, Lgr5, Vimentin, Axin2, 
Bambi and Lef1) in the GFPhigh2 population, compared to the GFPlow2 
population (Fig. 5B,C). Immunofluorescence revealed intense nuclear β-
catenin staining in the GFPhigh2 population, while E-cadherin staining at cell 
borders was strongly reduced (Fig. 5D, lower panel). In GFPlow2 cells, E-
cadherin was homogeneously high and β-catenin was low, while unsorted 
cells showed separated sub-clones of the different cell subpopulations (Fig. 
5D, middle and upper panels, respectively). The expression of the human 
stem cell markers CD44 and CD29 also correlated with Wnt/β-catenin activity; 
the fraction of CD44highCD29+ cells increased from 20% in the GFPlow1 
population to 91% in the GFPhigh2 population (Fig. S5A,B). Cells from different 
subpopulations were then cultured under anchorage-independent conditions 
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in serum-free medium to test their sphere-forming ability in the absence or 
presence of LF3 at 10 and 30 µM. All 4 cell populations formed spheres, but 
GFPhigh populations formed significantly more spheres than GFPlow 
populations (Fig. 5E,F), expressed TOP-GFP, and they were larger (Fig. 5E, 
3rd panel). Remarkably, treatment with LF3 reduced the number and size of 
spheres formed from GFPhigh populations, but had no significant impact on 
GFPlow cells (Fig. 5E,F). In sequential rounds of colony assays, GFPhigh cells 
produced similarly high number of spheres in each passage, but in the 
presence of LF3 sphere numbers were reduced continually (Fig. S5C). 
We had found previously that salivary gland squamous cell carcinomas were 
generated in mice that harbor β-catenin gain-of-function (β-catGOF) and Bmp 
receptor 1a loss-of-function (Bmpr1aLOF) mutations driven by Keratin14-Cre 
recombinase (Fig. 6A (16)). A CD24highCD29+ cell population (Fig. 6B, 
encircled in red in the left panel and following purification in the right panel) 
was characterized as salivary gland cancer stem cells by their potent sphere-
forming capacity in culture and their high tumorigenic potential following 
transplantation (16). Remarkably, the expression of stem cell-associated, 
chromatin modifier and Wnt target genes that are highly expressed in the 
salivary gland cancer stem cells were downregulated by LF3 at 30 µM, by 
ICG-001 at 25 µM, by the recently identified new Wnt inhibitor iCRT3 (27) at 
60 µM, and by β-catenin siRNA (Fig. 6C). LF3 also inhibited proliferation and 
sphere formation of these cells in dosage-dependent manners, as did ICG-
001 (Fig. 6D-F). Similarly, treatment with LF3 or ICG-001 induced 
differentiation of salivary gland cancer stem cells, as indicated by up-
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regulated expression of Amylase1, CA6 and Loricrin, and formation of hollow 
spheres in 3D matrigel culture (Fig. 6G, Fig. S6A,B) (16, 17).  
We also investigated Wnt/β-catenin target genes using gene expression 
profiling in salivary gland cancer stem cells treated with LF3 or ICG-001, since 
these inhibitors affect canonical Wnt signaling through different mechanisms, 
e.g., by inhibition of β-catenin-TCF/LEF1 and β-catenin-CBP interactions, 
respectively in this study (30). Several canonical Wnt target genes including 
Vimentin, Ephb2, Ash2l, Birc5 and Id2 were downregulated by both LF3 and 
ICG-001 (Fig. S6C). Overall, a majority of 325 genes (72.5%) were 
downregulated by both LF3 and ICG-001 (Fig. S6D), giving a high Pearson 
correlation coefficient of 0.73 (Fig. S6E). Gene clustering identified genes that 
were similarly or differentially regulated by LF3 and ICG-001 (Fig. S6F). Then 
a functional clustering of genes from the different groups was performed using 
DAVID bioinformatics resources. Genes that are involved in essential cellular 
processes such as cell cycle progression, macromolecular metabolism, 
transcription regulation, and others were similarly regulated by LF3 and ICG-
001 (Fig. S6F). Two clusters of genes which contribute to metal ion-binding 
and purine nucleotide-binding were differentially regulated by the two 
inhibitors, respectively (Table S3). 
LF3 reduces tumor growth and induces tumor differentiation 
To examine the effects of LF3 on tumor formation, GFPhigh and GFPlow SW480 
cells (see Fig. 5A) were injected subcutaneously into the back skin of 
NOD/SCID mice (1×104 cells per mouse). Within 40 days, all mice injected 
with GFPhigh cells developed tumors, whereas only one out of five mice 
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injected with GFPlow cells developed a tumor (Fig. 7A). When mice with 
GFPhigh cells were treated with LF3 at 50mg/kg through systemic i.v. injection 
for 3 weeks before tumor formation, tumor growth was significantly reduced 
(Fig. 7B, Fig. S7A). Inhibition was also observed, when treatment was started 
after tumors were palpable (Fig. S7B). No systemic toxicity, e.g., by weight 
loss was observed in the treated mice (Fig. S7C). Immunofluorescence 
showed that tumors induced by GFPhigh cells exhibited undifferentiated 
features including high expression of Lef-1 or Vimentin, nuclear location of β-
catenin and loss of E-cadherin, Keratin20 and Muc2 (Fig. 7C, Fig. S7D, upper 
panel). Remarkably, LF3-treated tumors became highly differentiated, as 
shown by expression of high E-cadherin, Keratin20 and Muc2, by membrane 
localization of β-catenin and by down-regulation of Lef-1 and Vimentin (Fig. 
7C, Fig. S7D, lower panel, quantified in Fig. 7D, Fig. S7E).  LF3 treatment did 
not disturb the normal histology of the gut of mice (Fig. S7F). These data 
show that LF3 has potent tumor inhibition and differentiation capacities in 
xenotransplanted tumors. 
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Discussion 
Wnt signaling’s crucial role in cancer biology has made it an important target 
to pursue in the development of new therapeutic strategies. So far, however, 
few rationally designed Wnt inhibitors have entered clinical trials, and of those 
being tried, some target Wnt ligand secretion or receptor binding (reviewed in 
(30)). In the present study, we focused on inhibiting the interaction between β-
catenin and TCF4, with the goal of overcoming deregulations of Wnt signaling 
caused by mutations of components that lie upstream in the pathway. The 
small molecule LF3 was identified in a biochemical screen using purified 
recombinant interaction partners. By specifically inhibiting the β-catenin/TCF4 
interaction, LF3 diminished Wnt-dependent biological characteristics of colon 
cancer cells including high proliferation and high motility. Remarkably, LF3 
also inhibited the self-renewal capacity of human colon and mouse salivary 
gland cancer cells and induced their differentiation. 
By comparing gene expression profiles of mouse salivary gland CSCs treated 
with LF3 or ICG-001, two compounds that target the transcription complexes 
at different positions, we observed a large overlap in dis-regulated genes, 
including well-known Wnt targets. This was surprising given the fact that the 
ICG-001 target CBP is known to interact with numerous transcription factors 
and can thus regulate many signaling systems (47). LF3 and ICG-001 
apparently inhibit deregulated Wnt signaling with a similar overall outcome. 
Further investigations are needed to understand whether the small sets of 
genes regulated by either TCF4 or CBP are critical for specific CSCs and 
tumors. Moreover, we show that the potency of LF3 is comparable with ICG-
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001 or iCRT3. LF3 at 50 mg/kg significantly reduced the growth of colon 
cancer stem cells during tumor formation while exhibiting no significant toxicity 
for mice. These results suggest that LF3 has the potential for further 
development with the aim of preclinical and clinical trials.  
Drug development, especially downstream in Wnt signaling, faces the 
challenge of finding inhibitors that target specific protein-protein interactions. 
Yet there is increasing evidence that small molecules that effectively dock 
onto hotspots of the interaction sites between partners and thus inhibit their 
interactions can indeed be found (reviewed in (48)). Such hotspots have been 
reported for the β-catenin/TCF4 interaction (32, 37). Efforts have been made 
to identify such inhibitors using, for instance, the compounds PKF115-584, 
CGP049090, PNU-74654 and iCRTs (20, 27, 49). In the present study, 
advanced biochemical screening techniques and the use of in-house synthetic 
compound libraries allowed us to identify compound LF3. The mechanistic 
details of the way LF3 disrupts β-catenin/TCF4 interaction remain to be shown; 
a strong hypothesis is that the negatively charged sulfonamide group of LF3 
may compete with Asp16 of TCF4 to bind to the positively charged pocket of 
β-catenin formed by Lys435. The hydrophobic tail of LF3 might insert itself 
into a hydrophobic cleft lined by the residues Cys466 and Pro463 of β-catenin 
to facilitate interaction (32, 37). Solving the structure of LF3 with the partner 
proteins will help answer these questions and will also permit medicinal 
chemistry approaches to be applied to improve the activity of the compound. 
Cancer stem cells are implicated in therapy resistance, metastasis formation 
and cancer relapse (50). In various cancers, CSCs are maintained by single 
signaling systems or by combinations of systems. If these are inhibited, 
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tumors may be forced to differentiate, as we have shown here in transplanted 
colon cancer cells. By inhibiting Wnt signaling, LF3 blocks the self-renewal of 
Wnt-high CSCs and induces their differentiation both in vitro and in xeno-
transplants. Remarkably, the population of Wnt-low cells in SW480 cells did 
not response to LF3 treatment. These cells appear to be supported by other 
signaling systems and driver mutations. Tumors that exhibit complex cellular 
heterogeneity may include different CSC populations supported by different 
signaling systems, and thus a combination of targeted therapies may be 
required to treat these cases in a personalized way. 
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Figure legends 
Figure 1 Compound LF3 disrupts the interaction between β-catenin and 
TCF4. (A) GST-tagged armadillo domain of β-catenin and His-tagged and 
biotinylated N-terminal region of TCF4 were prepared for AlphaScreen-based 
High Throughput Screening and ELISA to identify and verify compounds that 
disrupt the interaction between β-catenin and TCF4. (B) LF3 (structure and 
characteristics on the left) inhibits β-catenin/TCF4 interaction in both 
AlphaScreen and ELISA with IC50 of 1.65 and 1.82 µM, respectively. (C,D) 
Analogs of LF3 were tested in ELISA for their ability to inhibit β-catenin/TCF4 
interaction. Among all the analogs tested, LF3e and LF3g interfered with the 
interaction mildly, and only LF3h had an IC50 value comparable to LF3. 
Figure 2 LF3 specifically inhibits Wnt/β-catenin signaling in cells. (A,B) 
β-catenin was immunoprecipitated from protein extracts of HCT116 cells that 
were incubated with LF3 at increasing concentrations, and reduced TCF4 and 
LEF1 bound to β-catenin were shown by Western blotting. (C,D) TOP-GFP 
reporter cells were incubated with 3 μM CHIR99021 and with LF3, LF3h or 
LF3i at increasing concentrations. After 24 h, reduced GFP intensity was 
observed in LF3-treated cells. Compared to LF3h and LF3i, LF3 showed the 
most potent inhibition of Wnt signaling. (E) Hela cells were co-transfected with 
TOPflash-Luc plasmid (Wnt reporter) and pRL-SV40 plasmid (control for 
transfection), and stimulated with mWnt3a, CHIR99021, β-catenin activating 
mutant or β-catenin-Lef1 fusion in the presence or absence of LF3. LF3 
inhibited Wnt/β-catenin activation induced by mWnt3a, CHIR99021, β-catenin 
mutant, but not by β-catenin-Lef1. (F) The pRL-SV40 plasmid was co-
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transfected with different reporter plasmids including Oct-Luc, NF-кB-Luc or 
Notch-Luc into Hela cells. Different reporter activity was stimulated with 
specific treatments in the presence or absence of LF3. Compared to the 
inhibitory effect on the Wnt reporter, LF3 had no or very mild effects on other 
reporters. 
Figure 3 LF3 inhibits Wnt/β-catenin signaling in colon cancer cells. (A) 
HCT116 cells were incubated with 30 µM LF3 for 4 h and then cross-linked to 
immunoprecipitate β-catenin with bound DNA fragments. Reduced 
association of β-catenin with the Axin2 and c-Myc promoters by LF3 was 
shown by using specific primer pairs recognizing β-catenin binding-regions on 
the promoters by quantitative real-time PCR. (B) HCT116 cells were treated 
with various concentrations of LF3, 25 µM ICG-001 (for 24 h) or siβ-catenin 
(for 48 h), and downregulated mRNA levels of Wnt target genes were 
measured by quantitative real-time PCR. The effect of LF3 was comparable to 
ICG-001 and siβ-catenin treatment. (C,D,E,F) HCT116 (C,D) and SW480 (E,F) 
cells harboring different mutations in Wnt components were treated with LF3 
for 24 h. Downregulation of Wnt targets at the protein level was demonstrated 
by Western blotting (C,E; quantitation is in D,F). 
Figure 4 LF3 affects cell migration, proliferation and cell cycle 
progression of colon cancer cells. (A) SW480 cells were cultured with or 
without LF3 in the upper chambers of transwells, and stimulated to migrate by 
fetal bovine serum into the lower chambers. Reduced migration of SW480 
cells was observed after 24 h treatment of LF3. (B) Two colon cancer cell 
lines (HCT116 and HT29) and a breast cancer cell line (MCF7) were treated 
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with LF3 for 24 h and labeled with BrdU for 4 - 5 h to detect proliferating cells. 
BrdU-labeled cells were reduced upon LF3 treatment of colon cancer cells 
lines but not of MCF7 cells. (C) HCT116, HT29 and MCF7 cells were treated 
with LF3 for 24 h and fixed to analyze their cell cycle distribution. LF3 
increased cell numbers in the G1 and G2/M phases in HCT116 and HT29 
cells but not in MCF7 cells. 
Figure 5 LF3 inhibits the self-renewal of colon CSCs. (A) SW480 cells 
were stably transfected by the TOP-GFP reporter and analyzed for GFP 
expression by FACS. A heterogeneous GFP expression was observed in 
SW480 cells. (B) Different populations of cells were analyzed by real-time 
PCR for their mRNA levels of Wnt/β-catenin targets. Compared with SW480-
unsorted and GFPlow populations, the GFPhigh population showed much higher 
transcription of Wnt targets. (C,D) Immunofluorescence and Western blotting 
were used to detect protein levels of Wnt-controlled proteins in different cell 
populations. Compared with GFPlow cells, GFPhigh cells expressed high levels 
of β-catenin and Wnt target genes and low levels of E-cadherin. Nuclear 
localization of β-catenin was observed in GFPhigh cells. (E,F) Different 
populations of SW480 cells were cultured in non-adherent conditions with or 
without LF3 to test their ability to form spheres and the influence of LF3. 
GFPhigh populations formed more and larger spheres expressing GFP than 
GFPlow populations. LF3 reduced the number and the size of spheres formed 
from GFPhigh populations, but had no effect on the number and a very mild 
effect on the size of spheres formed from the GFPlow populations. 
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Figure 6 LF3 induces differentiation of mouse salivary gland CSCs. (A) 
Exon3 of β-catenin and exon2 of Bmpr1a, flanked by loxP sites, were deleted 
by Keratin14-Cre recombinase, resulting in salivary gland tumors with β-
catenin gain-of-function and Bmp receptor 1a loss-of-function mutations. (B) 
Based on surface marker expression, salivary gland CSCs (CD24highCD29+ 
cells) can be isolated from salivary gland tumors and cultured. (C) CSCs were 
treated with different Wnt inhibitors (for 24 h) and siβ-catenin (for 48 h), and 
mRNA levels of various genes were measured with quantitative real-time PCR. 
LF3 inhibited the transcription of Wnt target genes and genes that are 
important for keeping the stemness of CSCs, including stem cell signature 
genes and chromatin modifier genes, as efficiently as the other inhibitors. 
(D,E,F) Salivary gland CSCs were either cultured in adherent conditions to 
observe proliferation or in non-adherent conditions to observe self-renewal in 
the presence or absence of LF3 and ICG-001. LF3 dose-dependently 
inhibited proliferation and sphere formation of salivary gland CSCs, and the 
concentrations required of LF3 were comparable with those of ICG-001. (G) 
The differentiation marker Amylase1 of salivary gland CSCs was analyzed 
after treatment with LF3 or ICG-001. Both inhibitors induced the upregulation 
of Amy1. 
Figure 7 LF3 reduces tumor growth and induces differentiation of colon 
CSCs in vivo. (A) Tumor-free survival of NOD/SCID mice that were injected 
subcutaneously with unsorted, GFPlow and GFPhigh SW480 cells (1×104 cells 
per mouse). All mice (5/5) with GFPhigh cells, 4/5 mice with unsorted cells and 
1/5 mice with GFPlow cells developed tumors. (B) Mice xenografted with 
GFPhigh SW480 cells were treated i.v. with vehicle (n=10) or 50mg/kg LF3 
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(n=6) for 3 weeks, and tumor volumes were monitored over time. (C,D) 
Histological changes and expression changes of Lef1, Vimentin and E-
cadherin in LF3-treated tumors were demonstrated by H&E-staining and 
immunofluorescence. LF3 down-regulated the expression of Lef1 and 
Vimentin, and up-regulated E-cadherin. 10 tumors from the vehicle group and 
6 tumors from the LF3 group were evaluated. 







Supplementary Material – Portions of Materials and Methods and 
Supplementary Figure Legends 
 
Materials and Methods 
Protein purification 
GST-hβ-catenin (amino acids, aa 134-668), His-hTCF4 (aa 1-79) and mutant His-
hTCF4 (aa 1-79 containing D16A) were expressed in E. coli BL21 cells by IPTG 
induction, 1mM for 4 h. After induction, cells were sonicated and incubated in PBS 
containing 1% Triton X-100 for 30 min at 4 ˚C to release proteins from cells, and the 
cell debris was remove by centrifugation at 12,000 X g for 30 min at 4 ˚C. Cell lysates 
containing different recombinant proteins were loaded on GSTrap FF and HisTrap FF 
columns (GE), respectively. GSTrap FF columns were washed with PBS, and 
HisTrap FF columns were washed with PBS containing 0.5 M NaCl and 40 mM 
imidazole. After washing, GST-hβ-catenin was eluted with PBS containing 10 mM 
reduced glutathione, and His-hTCF4 and His-hTCF4 (D16A) were eluted with PBS 
contianing 500 mM imidazole. Purified proteins were dialyzed with PBS containing 1 
mM DTT and 20% glycerol overnight at 4 ˚C to remove reduced glutathione and 
imidazole, and stored at -80 ˚C. 
 
ELISA 
Nunc-immuno maxisorp 96 well plates (NUNC) were coated with purified His-
hTCF4 in coating buffer (50 mM carbonate-bicarbonate, pH 9.6) overnight at 4 
˚C, blocked with 1% BSA in PBS for 1 h, washed with PBS containing 0.05% 
Tween-20, and incubated with purified GST-hβ-catenin in the presence of 
series of concentrations of various purified proteins or compounds. 
Concentrations of purified His-hTCF4 and GST-hβ-catenin used in the ELISAs 
were determined by titration. Concentrations, which gave signals in linear 
range were chosen. To detect bound GST-hβ-catenin, plates were washed 
and incubated sequentially with anti-GST antibody (sc-101524, Santa Cruz) 
and HRP-conjugated anti-mouse antibody (715-035-150, Jackson 
ImmunoResearch laboratories), and measured with 1-Step Ultra TMB-ELISA 
(Thermo scientific) at 450 nm with a microplate reader Genios (Tecan).  
 
Establishment of TOP-GFP reporter cell lines 
The lentivirus particles (SABiosciences) encoding GFP under the control of a 
basal promoter element (TATA box) joined to tandem repeats of a consensus 
TCF/LEF binding site were transfected into HEK293 and SW480 cells. Stable 
clones were selected by puromycin (2 μg/ml) treatment. Next, fluorescence-
activated cell sorting (FACS) was performed to select HEK293 reporter cells 
that were sensitive to CHIR99021 (3 µM, Axon Medchem) treatment, and the 
different populations of SW480 reporter cells were separated based on their 
GFP intensity. 
 
Luciferase reporter assay 
Plasmids encoding a firefly luciferase reporter-gene under the control of 
different responsive elements were transfected into Hela cells with a pRL-
SV40 normalization reporter plasmid using Lipofectamine 2000 (Invitrogen). 
After desired treatments, cells were harvested in the passive lysis buffer 
(Promega), and 15 µl cell lysates were transferred to 96-well LumiNunc plates 
(Thermo Scientific). Firefly luciferase and Renilla luciferase were detected 
with D-luciferin buffer (75 mM Hepes, 4 mM MgSO4, 20 mM DTT, 100 µM 
EDTA, 0.5 mM ATP, 135 µM Coenzyme A, 100 µM D-Luciferin sodium salt, 
pH 8.0) and coelenterazine buffer (15 mM Na4PPi, 7.5 mM NaAc, 10mM 
CDTA, 400 mM Na2SO4, 25 µM APMBT and 1.1 µM coelenterazine, pH 5.0), 
respectively, using the CentroXS LB960 lumiometer (Berthold Technologies). 
 
Co-immunoprecipitation 
HCT116 cells were lysed in Co-IP buffer containing 50 mM Tris, pH7.5, 150 
mM NaCl, 0.2% NP-40, 10% Glycerol, 1 mM DTT and 1 mM PMSF. Cell 
lysates were pre-cleaned by protein G sepharose beads (GE Healthcare) at 
4 °C for 1 h. Pre-cleaned lysates were sequentially incubated with anti-β-
catenin antibody (610154, BD) at 4 ˚C overnight and subsequently with 
protein G sepharose beads for an additional 1 h. The beads were then 
washed, incubated with series of concentrations of LF3 for further 1 h and 
washed again. All the washing and incubation steps were carried out in Co-IP 
buffer. The bound proteins were eluted by boiling in SDS sample buffer and 
analyzed by Western blotting. 
 
Western blotting 
Protein samples were loaded onto 8-12% SDS-pages (separating gel: 8-12% 
acrylamide, 0.32% N,N -´Methylbisacrylamide, 375mM Tris, pH 8.8, 0.1% SDS, 
0.1% APS, 0.1% TEMED; stacking gel: 4% acrylamide, 0.1% N,N -´ 
Methylbisacrylamide, 125 mM Tris, pH 6.8, 0.1% SDS, 0.1% APS, 0.1% 
TEMED) and separated in electrophoresis running buffer (25 mM Tris, 20mM 
glycine, 2% SDS). Separated proteins were transferred onto PVDF 
membranes in the transfer buffer (25 mM Tris, 192 mM glycine, 3% SDS, 10% 
methanol). Non-specific binding of proteins on the membranes was blocked 
for 1 h at room temperature (RT) with blocking solution (4% BSA, 0.1% 
Tween20 in PBS) with constant shaking. The primary antibodies were diluted 
in blocking solution and incubated with the membranes at 4°C overnight with 
constant shaking. After washing in PBST (0.1% Tween20 in PBS), the 
membranes were incubated with HRP-conjugated secondary antibodies 
diluted in blocking solution for 1 h. After washing three times in PBST, the 
immuno-reactive bands were visualized with Western lightning 
chemiluminescence reagent plus (PerkinElmer) and Vilber Lourmat imaging 
system SL-3. Anti-TCF4 antibody (2953, Cell signaling) and anti-E-cadherin 
antibody (610181, BD) were used to analyze protein samples from Co-IP 
experiments. To evaluate Wnt target accumulation in HCT116 and SW480 
cells, cells were treated with LF3 at the indicated concentrations for 24 h and 
lysed in RIPA buffer (50 mM Tris, pH8.0, 1% NP-40, 0.5% deoxycholate, 0.1% 
SDS, 150mM NaCl). Axin2, cyclin D1 and c-Myc were detected using anti-
Axin2 (2151, Cell signaling), anti-cyclin D1 (sc-718, Santa Cruz) and anti-c-
Myc (sc-40, Santa Cruz) antibodies, respectively.  
 
Immunofluorescence 
MDCK and SW480 cells were cultured on 8-well CultureSlides (BD). After 
desired treatments, cells were fixed with 4% formaldehyde in PBS for 15 min, 
and blocked in PBS with 1% BSA and 0.3% Triton X-100 for 1 h. Slides were 
then sequentially incubated with anti-β-catenin and anti-E-cadherin primary 
antibodies at 4 ˚C overnight, and fluorchrome-conjugated secondary antibody 
at RT for additional 1h. After washing with PBS, slides were covered with 
Immunomount (Thermo Scientific), and the fluorescence images were 
recorded using Axio imager.Z1m and AxioCam MRm (Carl Zeiss). 
 
Chromatin immunoprecipitation 
After treating with LF3 for 4 h, HCT116 cells were fixed with 1% formaldehyde 
in PBS and incubated in swelling buffer (25mM Hepes, pH7.9, 1.5mM MgCl2, 
10mM KCl, 0.1% NP-40, 1mM DTT and 0.5mM PMSF) to prepare for 
extraction of nuclei. Afterwards, chromatin was sheared by sonication in 
sonication buffer (50mM Hepes, pH7.9, 140mM NaCl, 1mM EDTA, 1% Triton 
X-100, 0.1% Na-deoxycholate, 0.1% SDS and 0.5mM PMSF) and incubated 
with 2 μg of anti-β-catenin antibody (610154, BD) and 25 µl Dynabeads 
Protein G (100-03D, Life Technologies) over night at 4°C. The beads were 
washed successively with 1 ml sonication buffer, 1 ml high salt buffer (same 
as sonication buffer except 500 mM NaCl) and 1 ml LiCl wash buffer (20 mM 
Tris, pH 8.0, 1 mM EDTA, 250 mM LiCl, 0.5% NP-40, 0.5% Na-deoxycholate, 
0.25 mM PMSF). All washing steps were repeated twice and performed on a 
rotating wheel at 4°C. Chromatin was eluted with elution buffer (50 mM Tris, 
pH 8.0, 1 mM EDTA, 1% SDS, 50 mM NaHCO3) and purified with PCR 
purification kit (28104, Qiagen). Enriched chromatin regions were 
characterized by quantitative real time PCR (qRT-PCR). 
 
 
 
 
 
Table S1. Primer sequences for ChIP experiment 
Chromatin region Primer Sequence 
Axin2 promoter F TCTGGTAGCATTATGGCCATCGCA 
 R AAAGTCCTCCAAGCCCAAATTCCC 
c-Myc promoter F AATTAAACGTCCGGTTTGTCCGGG 
 R AAGGTGCTAGACGGGAGAATATGG 
 
Gene transcription analyses with qRT-PCR 
After desired treatments, cells were lysed in TRIzol, and mRNA was extracted 
according to the standard TRIzol protocol (Invitrogen). RNA concentrations 
and purities were determined by the Nanodrop ND1000 spectrophotometer 
(Thermo Scientific). To reverse transcribe mRNA into cDNA, M-MLV reverse 
transcriptase (Promega) and random primers (Invitrogen) were used with 5μg 
of total RNA, following the manufacturer’s protocol. qRT-PCR was performed 
in a iQ5 Multicolor Real-Time PCR Detection System (Bio-Rad) using 10 µl 2X 
SYBR® Green (Thermo scientific), 0.5μl cDNA and 0.5μl of 10μM primer 
mixes. The primers were designed as to have an annealing temperature of 
60°C and an amplicon length of 100-200bp in the following program (95°C 15 
min; 94°C 20 sec, 60°C 45 sec, 72 °C 10 sec; 40 cycles).  
 
Table S2. Primer sequences for qRT-PCR 
Species Gene Primer Sequence 
Human Bmp4 F TCTATGTGGACTTCAGCGATGTGG 
  R AATTGACCAGGGTCTGCACAATGG 
 Axin2 F TCAAGTGCAAACTTTCGCCAACCG 
  R TGGTGCAAAGACATAGCCAGAACC 
 Survivin F AGCCCTTTCTCAAGGACCACC 
  R CTTGAAGCAGAAGAAACACTGGGC 
 Bambi F ATTCGATGCTACTGTGATGCTGCC 
  R ATTCCAATGTGGGTATGGTGGTGC 
 c-Myc F TCTCCACACATCAGCACAACTACG 
  R TGTGTTCGCCTCTTGACATTCTCC 
 β-catenin F TTCGAAATCTTGCCCTTTGTCCCG 
  R AATTCGGTTGTGAACATCCCGAGC 
 Lef1 F ACCTCAGGTCAAACAGGAACATCC 
  R AGTACACTCAGCAACGACATTCGC 
 Lgr5 F TGCTTACCAGTGCTGTGCATTTGG 
  R TGCACTGAATGAAGGGCTTTCAGG 
 β-actin F GCATCCACGAAACTACCTTCAACTCC 
  R TTGATCTTCATTGTGCTGGGTGCC 
Mouse Nr5a2 F GGGGCAGAAATAAGTTTGGGC 
  R TTGGAGGCGGAATGAATGTTC 
 Abcb1b F TTATGCTGCTTGTTTCCGGTTCGG 
  R TTTGGCTTTCGCATAGTCAGGAGC 
 Lrrc34 F TCAAGGGAATAAACCTGAACCGGC 
  R ATTGCAGCTGACATCAAGGTAGCG 
 Dpp55 F GAAATATCTGTTTGGCCCACAGGG 
  R GCCATGGACTGAAGCATCCATTTAGC 
 Hells F TTCGGAAATGTAATGGACAGC 
  R GGGCCACATACAAGAAAAGG 
 Mll1 F AACAAGCATGGATCTCCCAATGCC 
  R ACATGTAGCAACCAATGCCCTTGC 
 Ash2l F AAATGGTGTCAATCAGGGTGTGGC 
  R ACATCAGCCAGTGTGTGTTCTACC 
 Bambi F ATCAGCATGACAGCAGCAGAAACC 
  R TCTTGGAATGGTGTCCGTGAAAGC 
 c-Myc F TCCTGAAGCAGATCAGCAACAACC 
  R TGCTTGAATGGACAGGATGTAGGC 
 Bmp2 F TGTCTTCTAGTGTTGCTGCTTCCC 
  R TGAGCAGCCTCAACTCAAATTCGC 
 β-actin F TCGTGCGTGACATCAAAGAGAAGC 
  R ATGGATGCCACAGGATTCCATACC 
 
Proliferation analyses with BrdU 
HCT116, HT29 and MCF7 cells were treated with indicated concentrations of 
LF3 for 24 h. 3-6 h before collecting cells, 10 µM BrdU was added into the 
culture medium. After trypsinization, single cell suspensions were fixed in 70% 
ethanol on ice for 30 min, treated with 2 M hydrochloric acid at RT for 30 min, 
and sequentially incubated with anti-BrdU antibody (ab6326, Abcam) and 
DyLight488-conjucated anti-rat antibody (712-485-150, Jackson 
ImmunoResearch laboratories) in PBS with 0.2% Tween-20 and 1% BSA. 
BrdU-positive cells were detected by the FACSCalibur system (BD). 
 
Cell migration assays 
Cell motility was assessed using 24-well transwells (pore diameter: 8 µm, 
Corning). SW480 cells were seeded in the upper chamber in serum-free 
DMEM with 0.1% BSA. 20% serum was supplemented to medium in the lower 
chamber. After incubation with different concentrations of LF3 for 24 hours at 
37°C, nonmigrant cells were scraped off using a cotton swab, and the 
migrated cells on the filters were stained with crystal violate, photographed 
and counted. 
 
Cell death and apoptosis analyses 
HCT116 cells were treated with 60 µM LF3 or 1μg/ml puromycin for 24 h, and 
then trypsinized to single cell suspensions. Fresh cells were incubated with 5 
μg/ml propidium iodide (Sigma) in PBS for 10 min and analyzed for accidental 
cell death using the FACSCalibur system (BD). For the apoptosis analyses, 
cells fixed with 3% formaldehyde were sequentially incubated with anti-
cleaved-caspase3 antibody (9661, Cell signaling) and DyLight488-conjugated 
secondary antibody (711-485-152, Jackson ImmunoResearch laboratories) in 
PBS with 0.5% BSA. The percentage of cleaved-caspase3-positive cells was 
analyzed by the FACSCalibur system (BD). 
 
Cell cycle analyses 
HCT116, HT29 and MCF7 cells were treated with the indicated concentrations 
of LF3 for 24 h, trypsinized to make single cell suspensions and fixed in 70% 
ethanol overnight. After washing with PBS, cells were incubated in Propidium 
iodide (PI)-staining buffer (10mM Tris, pH7.5, 50 µg/ml PI, 5 mM MgCl2 and 
10 μg/ml Rnase A) at 37 °C for 30 min. DNA contents of cells were measured 
by the FACSCalibur system (BD) and analyzed by the software FlowJo (Tree 
Star). 
 
Cell surface marker analysis 
All cell surface markers were antibody-stained in PBS with 5% BSA for 15 min 
at RT. FITC conjugated anti-CD44 (55478, BD) and PE-Cy5 conjugated anti-
CD29 (559882, BD) antibodies were used to characterize SW480 cells. PE-
conjugated anti-CD24 (553262, BD) and Alexa700 conjugated anti-CD29 
(102218, Biolegend) antibodies were used to analyze mouse salivary gland 
cancer stem cells. 
 
Gene expression profiling  
After desired treatments, total RNA of salivary gland CSCs were extracted 
according to the standard TRIzol protocol (Invitrogen). RNA was purified with 
RNeasy kit (Qiagen) and prepared with TotalPrep RNA amplification kit 
(Illumina) for the microarray analysis using MouseRef-8 v2.0 expression 
beadchip Kit. Microarray data (GEO accession: GSE73732) were analyzed 
and exported with the software Genome Studio (Illumina). Pearson correlation 
was calculated with http://www.wessa.net/rwasp_correlation.wasp. Expression 
clustering was calculated and visualized with software Cluster and TreeView 
(Stanford University), respectively. Functional clustering of interesting genes 
was performed with http://david.abcc.ncifcrf.gov/.  
 
Supplementary Figure Legends 
Fig. S1 Technology and protein production for the primary High 
Throughput Screen (HTS). (A,B) Schematic illustrations of AlphaScreen and 
ELISA with purified proteins. (C) Inhibition of the TCF4/β-catenin interaction in 
the presence of various recombinant fusion proteins in competitive ELISAs. (D) 
Schematic illustration of the screening process: 16,000 compounds were 
screened in the primary screen with the AlphaScreen technology; 18 out of 
132 primary hits were validated in both AlphaScreen and ELISAs. (E,F) 5 hits 
(labeled LF1-5) showed an IC50 of less than 10 µM in both assays. 
Fig. S2 Specific inhibition of Wnt signaling by LF3. (A) Scheme of 
simplified Wnt signaling and interfering compounds: CHIR99021 and XAV939 
exert their agonistic and antagonistic effects, respectively, on the β-catenin 
destruction complex, while ICG-001 and LF3 inhibit Wnt signaling by targeting 
the transcription complex. (B) Inhibition of Wnt/-catenin signals by different 
Wnt inhibitors: TOP-GFP reporter cells were treated with various 
concentrations of CHIR99021 and different Wnt inhibitors, LF3 (30 µM), ICG-
001 (3 µM) or XAV939 (1 µM). (C) The pRL-SV40 plasmid was co-transfected 
with different reporter plasmids including TOPflasch-Luc, Oct-Luc, NF-кB-Luc 
or Notch-Luc into Hela cells. Different reporter activities were stimulated with 
specific treatments at different dosages. The dosages (arrowheads) that 
induced moderate activation of individual pathways were chosen to assess 
the effect of LF3 on these pathways. (D) MDCK cells were treated with 60 µM 
LF3 or 40 U/ml HGF, and fixed at 24 h to visualize the distribution of E-
cadherin and β-catenin by immunofluorescence. Membrane co-localization of 
E-cadherin and β-catenin remained unchanged in LF3-treated cells as in 
control cells, but it was significantly altered upon HGF treatment. (E,F) β-
catenin was immunoprecipitated from protein extracts of HCT116 cells that 
were incubated with LF3 at increasing concentrations, and E-cadherin bound 
to β-catenin was not changed, as shown by Western blotting. (G) After 5 min 
treatment with trypsin, the protein levels of E-cadherin and β-catenin in MDCK 
cells were analyzed. (H) After trypsinization, MDCK cells were kept in 
complete medium to reform cell-cell adhesion. Cells were fixed at different 
time points for analyzing the distribution of β-catenin by immunofluorescence. 
Fig. S3 Inhibition of Wnt signaling by LF3 in colon cancer cells. SW620 
(A,B), HCT15 (C,D), SW48 (E,F) and LS174T (G,H) colon cancer cells 
harboring different mutations in canonical Wnt components were treated with 
LF3 for 24 h. Downregulation of Wnt targets at the protein level was 
demonstrated by Western blotting. 
 
Fig. S4 LF3 doesn’t cause apoptosis or cell death. HCT116 cells were 
treated with 60 µM LF3 or 1 µg/ml puromycin for 24 h and fixed for antibody 
staining of cleaved caspase3 (A), or freshly stained by PI (B) to observe cell 
membrane integrity. 
 
Fig. S5 CSC markers and self-renewal of GFPhigh SW480 cells. (A,B) 
SW480 cells were double-stained with antibodies against the CSC markers 
CD44 and CD29 and analyzed by flow cytometry. Two populations of cells, 
CD44highCD29+ and CD44lowCD29+, were observed. (C) The self-renewal of 
GFPhigh cells was tested in sequential rounds of colony assays in the 
presence of LF3. LF3 reduced the colony numbers continually in each 
passage. 
 
Fig. S6 Influence of LF3 on gene profiling and differentiation of mouse 
salivary gland CSCs. (A) The differentiation markers CA6 and Loricrin of 
salivary gland CSCs were analyzed by qPCR after treatment with LF3. (B) 
Salivary gland CSCs were cultured in matrigel to form 3D structures. 
Undifferentiated structures (filled spheres) and differentiated structures 
(hollow spheres) were recorded and quantified after 14 days. (C) Salivary 
gland CSCs were treated with 30 µM LF3 or 25 µM ICG-001 for 24 h and 
collected to perform gene profiling using Illumina microarrays. The heat map 
of a panel of canonical Wnt targets demonstrated that LF3 and ICG-001 
inhibited Wnt signaling, but showed slight differences in choosing their targets. 
(D,E) The overlap between genes downregulated by LF3 and ICG-001 and 
the “Pearson correlation coefficient” indicate the largely similar influence of 
LF3 and ICG-001 treatment on gene profiling. (F,G) Expression clustering 
revealed groups of genes that were differentially or similarly regulated by 
different compounds. Genes in different groups were studied by function 
clustering using the DAVID bioinformatics resources.  
 
Fig. S7 LF3 reduces tumor growth without showing toxicity in vivo. (A) 
Mice xenografted with GFPhigh SW480 cells were treated i.v. with vehicle 
(n=10) or 50mg/kg LF3 (n=6) for 3 weeks, and the tumor weight was 
measured on day 45.  (B) Mice xenografted with GFPhigh SW480 cells were 
treated i.v. with vehicle (n=6) or 50mg/kg LF3 (n=6) after palpable tumors had 
developed, and the tumor volumes were monitored over time. (C) The body 
weight of mice in control and treated groups was monitored over time. (D,E) 
Expression changes of KRT20 and MUC2 in LF3-treated tumors were 
examined by immunofluorescence and quantified. 10 tumors from the vehicle 
group and 6 tumors from the LF3 group were evaluated. (F) H&E staining of 
colon, small intestine and stomach of control and LF3-treated mice. 







